Skip to main content
Account

Table 1 Effect of intervention compared placebo in meta-analysis results

From: Evaluation of bone health and fracture risk in type 2 diabetes: a network meta-analysis of anti-diabetic treatments versus placebo

Outcome

Total Effect

P-value

Heterogeneity

Subgroup

difference

GLP1RA

SGLT2i

DPP4i

Metformin

TZD

Fracture | OR [95% CI]

 Overall Fracture

0.92 [0.84, 1.01]

0.07

0%

0.68

0.84 [0.69, 1.02]

0.97 [0.84, 1.12]

0.87 [0.71, 1.06]

0.96 [0.09,10.73]

1.33 [0.54, 3.29]

 Vertebral Fracture

0.81 [0.62, 1.04]

0.10

0%

0.82

0.68 [0.43, 1.10]

0.86 [0.59, 1.26]

0.88 [0.52, 1.50]

NA

0.41 [0.03, 6.66]

 Non-Vertebral Fracture

0.95 [0.85, 1.06]

0.34

0%

0.43

0.83 [0.67, 1.01]

1.03 [0.88, 1.21]

0.95 [0.78, 1.17]

NA

1.09 [0.36, 3.30]

 Treatment based Hip Fracture

0.93 [0.80, 1.09]

0.36

0%

0.94

0.89 [0.67, 1.19]

0.91 [0.71, 1.16]

1.01 [0.76, 1.34]

NA

0.87 [0.11, 6.77]

 Vertebral + Hip Fracture

0.89 [0.78, 1.02]

0.10

0%

0.80

0.82 [0.65, 1.05]

0.90 [0.73, 1.10]

0.98 [0.76, 1.25]

NA

0.67 [0.13, 3.49]

 Multiple Fracture

0.85 [0.45, 1.62]

0.85

0%

0.79

1.19 [0.36, 3.96]

0.83 [0.24, 2.85]

0.70 [0.26, 1.85]

NA

NA

Anatomy Fracture | OR [95% CI]

 Vertebral Column Fracture

0.78 [0.58, 1.05]

0.11

0%

0.68

0.64 [0.39, 1.05]

0.82 [0.48, 1.37]

0.98 [0.57, 1.67]

NA

NA

 Lower Extremity Fracture

0.96 [0.85, 1.08]

0.51

0%

0.63

0.84 [0.67, 1.06]

1.00 [0.82, 1.22]

1.01 [0.80, 1.26]

NA

1.19 [0.38, 3.74]

 Upper Extremity Fracture

0.90 [0.77, 1.06]

0.20

0%

0.81

0.83 [0.62, 1.11]

0.98 [0.77, 1.25]

0.84 [0.60, 1.19]

NA

0.71 [0.09, 5.37]

 Pelvic Girdle Fracture

0.91 [0.71, 1.16]

0.45

0%

0.92

1.01 [0.64, 1.61]

0.83 [0.56, 1.21]

0.94 [0.59, 1.50]

NA

0.87 [0.11, 6.77]

 Cranial and Facial Fracture

1.01 [0.70, 1.47]

0.95

0%

0.42

0.84 [0.40, 1.75]

1.52 [0.83, 2.80]

0.79 [0.43, 1.45]

NA

0.51 [0.03, 8.18]

 Thoracic Cage Fracture

0.87 [0.67, 1.13]

0.28

0%

0.63

0.74 [0.45, 1.23]

1.08 [0.71, 1.63]

0.78 [0.47, 1.32]

NA

0.54 [0.06, 4.96]

BMD | SMD [95% CI]

 Femoral neck BMD

0.02 [-0.07, 0.12]

0.64

0%

0.87

NA

0.03 [-0.09, 0.16]

NA

0.00 [-0.19, 0.19]

-0.10 [-0.62, 0.43]

 Total hip BMD

-0.12 [-1.09,0.85]

 < 0.01

98%

 < 0.01

2.50 [1.81, 3.18]

0.00 [-0.15, 0.16]

NA

-2.74 [-3.01, -2.47]

-0.35 [-0.77, 0.07]

 Lumber spine BMD

0.06 [-0.03, 0.16]

0.21

21%

0.22

NA

0.04 [-0.08, 0.15]

NA

0.00 [-0.19, 0.19]

0.49 [-0.03, 1.01]

  1. BMD Bone Mineral Density, DPP4i dipeptidyl peptidase 4 inhibitor, GLP1RA Glucagon-like-peptide-1 receptor agonists, NA not applicable, OR Odds ratio, SGLT2i Sodium-glucose cotransporter 2 inhibitor